newsfilter
← Latest News
PR Newswire·

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...